DETERMINE news hub
Discover the latest updates on the DETERMINE trial including updates on our progress, site openings, and partnership initiatives.
Latest news
Beyond borders: going global with clinical trials
Lars Erwig, Director of the Cancer Research UK Centre for Drug Development, talks about the need for global collaboration in clinical trials and international partnerships to pool expertise, resources and patients.
Collaboration for implementation of precision cancer medicine in Europe
PCM4EU (Personalized Cancer Medicine for all EU citizens) and PRIME-ROSE (Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials) aim to facilitate implementation of precision cancer medicine in Europe.
In other news
2023
- The Guardian: Patients with rare cancers given hope by UK-led ‘drug-match’ trial
- Citeline: The Script Award categories 2023
- The Herald: Scotland cancer: First-of-its-kind trial to test new treatment
- The Independent: Scots with rare cancers to test new treatment in first-of-its-kind trial
- The Times: Scotland cancer patients will be first to try precision treatment
- The Standard: Scots with rare cancers to test new treatment in first-of-its-kind trial
- The National: Scots with rare cancers to test new treatment in first-of-its-kind trial
- Accelerate: Fair for AYA stamp
- Cancer Research Horizons: Cancer Research UK joins European precision cancer medicine trial consortium
- PRIME-ROSE: Official Opening of the Horizon EU Cancer Mission PRIME-ROSE project
- Cancer Research Horizons: The DETERMINE trial: showcasing Cancer Research UK’s unique position in the pharma industry
2022
- Bionow: Introducing the 2022 Bionow Awards Shortlist!
- Bionow: A fabulous night of accolades at the 2022 Bionow Awards Dinner
- Cancer Research Horizons: Precision medicine trial opens for rare adult and paediatric cancers
- Cancer Research Horizons: Novartis joins Cancer Research UK trial for rare cancers
2021
- The University of Manchester: Cancer researchers across the UK join forces to find drugs for rare cancers